MED · Company research
Medifast, Inc. (MED): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
37records availableOther
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside - Zacks Investment Research | Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 0.6 |
| Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside - Yahoo Finance | Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Medifast (NYSE:MED) Stock Bumped Up to Strong-Buy by Zacks Research - MarketBeat | Medifast (NYSE:MED) Stock Bumped Up to Strong-Buy by Zacks Research MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| Quarterly results are scheduled before markets open Oct. 26, with Medifast's call at 8:30 a.m. - Stock Titan | Quarterly results are scheduled before markets open Oct. 26, with Medifast's call at 8:30 a.m. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| Best Momentum Stocks to Buy for October 14th | Zacks highlights three stocks with Rank #1 buy ratings and strong momentum: Nucor Corporation (steel manufacturing) with 8.6% three-month gains and 6.5% earnings estimate increase; Cinemark Holdings (cinema exhibition) with 29.5% three-month gains and 7.3% earnings estimate increase; and Medifast Inc (weight management) with 10.0% three-month gains and 47.2% earnings estimate increase. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Best Momentum Stocks to Buy for October 14th | Zacks highlights three stocks with Rank #1 buy ratings and strong momentum: Nucor Corporation (steel manufacturing) with 8.6% three-month gains and 6.5% earnings estimate increase; Cinemark Holdings (cinema exhibition) with 29.5% three-month gains and 7.3% earnings estimate increase; and Medifast Inc (weight management) with 10.0% three-month gains and 47.2% earnings estimate increase. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| EGB OE TS.Z./FRESENIUS MED (AT0000A2YGK2.VI) Stock Forum & Discussion - Yahoo Finance - Yahoo! Finance Canada | EGB OE TS.Z./FRESENIUS MED (AT0000A2YGK2.VI) Stock Forum & Discussion - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| New Strong Buy Stocks for October 14th | Five companies have been added to the Zacks Rank #1 (Strong Buy) list based on significant increases in consensus earnings estimates over the last 60 days. The stocks span multiple sectors including footwear, steel manufacturing, cloud computing, weight management, and insurance. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| New Strong Buy Stocks for October 14th | Five companies have been added to the Zacks Rank #1 (Strong Buy) list based on significant increases in consensus earnings estimates over the last 60 days. The stocks span multiple sectors including footwear, steel manufacturing, cloud computing, weight management, and insurance. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Can Hormel Foods Keep Expanding Margins Despite Softer Retail Volumes? | Hormel Foods expanded adjusted operating margins by 60 basis points to 9% in Q3 2026 despite softer retail volumes. The company benefited from lower pork commodity prices, strong foodservice performance, and disciplined cost management. However, retail volumes declined due to business exits and pricing elasticity, while the company faces headwinds from elevated beef, freight, and logistics costs. Hormel is using pricing strategies and efficiency gains to sustain profitability. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -0.25 | 1 |
| Can Hormel Foods Keep Expanding Margins Despite Softer Retail Volumes? | Hormel Foods expanded adjusted operating margins by 60 basis points to 9% in Q3 2026 despite softer retail volumes. The company benefited from lower pork commodity prices, strong foodservice performance, and disciplined cost management. However, retail volumes declined due to business exits and pricing elasticity, while the company faces headwinds from elevated beef, freight, and logistics costs. Hormel is using pricing strategies and efficiency gains to sustain profitability. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -0.25 | 1 |
| After repaying $935K to its CEO, Adia Med has only clinic and equipment leases left. - Stock Titan | After repaying $935K to its CEO, Adia Med has only clinic and equipment leases left. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| 1 Small-Cap Stock with Impressive Fundamentals and 2 Facing Challenges - StockStory | 1 Small-Cap Stock with Impressive Fundamentals and 2 Facing Challenges StockStory | View source ↗ | StockStory | Oct 13, 2026 | neutral | 0 | 0.6 |
| Medifast (NYSE:MED) Shares Break Above 200-Day Moving Average - What's Next? - MarketBeat | Medifast (NYSE:MED) Shares Break Above 200-Day Moving Average - What's Next? MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| BeBetter Med, Inc. Class A Actuals & Estimates (SSE:688759) - TradingView | BeBetter Med, Inc. Class A Actuals & Estimates (SSE:688759) TradingView | View source ↗ | TradingView | Oct 11, 2026 | neutral | 0 | 0.6 |
| MEDICLIN Aktiengesellschaft (MED.DE) stock price, news, quote and history - Yahoo Finance Singapore | MEDICLIN Aktiengesellschaft (MED.DE) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 10, 2026 | neutral | 0 | 0.6 |
| AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress - Simply Wall Street | AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| AngioDynamics stock slips 4% despite beating estimates on Med Tech growth - Investing.com | AngioDynamics stock slips 4% despite beating estimates on Med Tech growth Investing.com | View source ↗ | Investing.com | Oct 8, 2026 | neutral | 0 | 0.6 |
| AngioDynamics stock slips 4% despite beating estimates on Med Tech growth - Yahoo Finance | AngioDynamics stock slips 4% despite beating estimates on Med Tech growth Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Can Hormel Foods Tackle Input Costs With Pricing and Efficiency? | Hormel Foods (HRL) is managing elevated input costs through pricing actions, supply chain improvements, and efficiency gains. While lower pork commodity prices began benefiting in Q3, the company still faces headwinds from higher beef, freight, logistics, and fuel costs. Management expects greater benefits from lower pork costs in future quarters as it implements multiple levers to protect profitability. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | neutral | 0 | 1 |
| Can Hormel Foods Tackle Input Costs With Pricing and Efficiency? | Hormel Foods (HRL) is managing elevated input costs through pricing actions, supply chain improvements, and efficiency gains. While lower pork commodity prices began benefiting in Q3, the company still faces headwinds from higher beef, freight, logistics, and fuel costs. Management expects greater benefits from lower pork costs in future quarters as it implements multiple levers to protect profitability. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | neutral | 0 | 1 |
| Can Medifast's Better Client Retention Support Revenue Stabilization? | Medifast (MED) reported Q2 2026 revenues of $76.4 million, down 27.6% year-over-year due to a 48.7% decline in active earning coaches to 11,700. However, the company showed positive signs with revenue per active coach increasing 41% to $6,529 for a third consecutive quarter, improved client retention, and strong referral program performance. Management expects Q3 revenues of $60-$80 million with continued coach productivity improvements. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.5 | 1 |
| Can Medifast's Better Client Retention Support Revenue Stabilization? | Medifast (MED) reported Q2 2026 revenues of $76.4 million, down 27.6% year-over-year due to a 48.7% decline in active earning coaches to 11,700. However, the company showed positive signs with revenue per active coach increasing 41% to $6,529 for a third consecutive quarter, improved client retention, and strong referral program performance. Management expects Q3 revenues of $60-$80 million with continued coach productivity improvements. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.5 | 1 |
| A stem cell distributor can buy another 10% of Adia Labs for $500,000 within two years - Stock Titan | A stem cell distributor can buy another 10% of Adia Labs for $500,000 within two years Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Why Do You Keep Gaining Weight Back After Losing It | Trilivy, a metabolic health system by Medifast, identifies five key factors that drive weight regain: slowed metabolism, hormonal changes, lack of human support, set point theory, and metabolic adaptation. The company's Metabolic Synchronization® framework addresses these through lean mass preservation and visceral fat reduction, with clinical data showing 98% lean mass retention and 14% visceral fat reduction at 16 weeks. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Why Do You Keep Gaining Weight Back After Losing It | Trilivy, a metabolic health system by Medifast, identifies five key factors that drive weight regain: slowed metabolism, hormonal changes, lack of human support, set point theory, and metabolic adaptation. The company's Metabolic Synchronization® framework addresses these through lean mass preservation and visceral fat reduction, with clinical data showing 98% lean mass retention and 14% visceral fat reduction at 16 weeks. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Will Innovation and Digital Expansion Efforts Drive Clorox's Growth? | The Clorox Company is executing a strategic transformation focused on rebuilding market share and enhancing growth through the GOJO Industries acquisition, which significantly expands its health and hygiene portfolio to over half of net sales. The company has completed its five-year digital transformation program and expects productivity benefits from fiscal 2027 onwards. Clorox is increasing innovation spending in health, wellness, and pet care categories while improving brand relevance through targeted promotions and packaging improvements. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.5 | 1 |
| Will Innovation and Digital Expansion Efforts Drive Clorox's Growth? | The Clorox Company is executing a strategic transformation focused on rebuilding market share and enhancing growth through the GOJO Industries acquisition, which significantly expands its health and hygiene portfolio to over half of net sales. The company has completed its five-year digital transformation program and expects productivity benefits from fiscal 2027 onwards. Clorox is increasing innovation spending in health, wellness, and pet care categories while improving brand relevance through targeted promotions and packaging improvements. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.5 | 1 |
| Here's Why Shares of BranchOut Food Surge 89% in a Year | BranchOut Food Inc. (BOF) stock has surged 89.1% over the past year, significantly outperforming its industry peers and the broader market. The rally is driven by the company's transition from episodic product launches to recurring retail programs, rapid expansion of its ingredient business, and improving manufacturing utilization. With booked orders providing greater revenue visibility and potential for substantial margin recovery through higher factory utilization, investors are increasingly confident in BOF's ability to leverage its existing infrastructure for higher volumes. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.333 | 1 |
| Here's Why Shares of BranchOut Food Surge 89% in a Year | BranchOut Food Inc. (BOF) stock has surged 89.1% over the past year, significantly outperforming its industry peers and the broader market. The rally is driven by the company's transition from episodic product launches to recurring retail programs, rapid expansion of its ingredient business, and improving manufacturing utilization. With booked orders providing greater revenue visibility and potential for substantial margin recovery through higher factory utilization, investors are increasingly confident in BOF's ability to leverage its existing infrastructure for higher volumes. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.333 | 1 |
| Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,544 Shares - MarketBeat | Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,544 Shares MarketBeat | View source ↗ | MarketBeat | Oct 1, 2026 | neutral | 0 | 0.6 |
| A preset trading plan covers Medifast (MED) director Chard's trust sales of 9,545 and 9,544 shares. - Stock Titan | A preset trading plan covers Medifast (MED) director Chard's trust sales of 9,545 and 9,544 shares. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,545 Shares - MarketBeat | Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,545 Shares MarketBeat | View source ↗ | MarketBeat | Sep 30, 2026 | neutral | 0 | 0.6 |
| Four stock-award lots make up Medifast (MED) officer Daniel Chard’s planned sale of 9,545 shares. - Stock Titan | Four stock-award lots make up Medifast (MED) officer Daniel Chard’s planned sale of 9,545 shares. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Medifast director Kiai Parsa buys $529k in MED stock - Investing.com | Medifast director Kiai Parsa buys $529k in MED stock Investing.com | View source ↗ | Investing.com | Aug 28, 2026 | neutral | 0 | 0.6 |
| 3 Reasons to Sell MED and 1 Stock to Buy Instead - Yahoo Finance | 3 Reasons to Sell MED and 1 Stock to Buy Instead Yahoo Finance | View source ↗ | Yahoo Finance | Aug 21, 2026 | neutral | 0 | 0.6 |
| Why Medifast (MED) Stock Is Trading Up Today - StockStory | Why Medifast (MED) Stock Is Trading Up Today StockStory | View source ↗ | StockStory | Aug 4, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.